B48

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

Retrieved on: 
星期一, 五月 20, 2024
Lazarus, Rash, Patient, Diarrhea, Theme, Data, Risk, FVC, Nausea, PPF, FCCP, Disease, Safety, Poster, Conference, American Thoracic Society, Efficacy, Idiopathic pulmonary fibrosis, Indigestion, Pulmonary fibrosis, Biomarker, ATLAS, ATS, B48, Fatigue, IPF, WRVS, Vomiting, Pharmaceutical industry

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Avalyn), a clinical-stage biopharmaceutical company focused on development of inhaled therapies for treatment of life-threatening pulmonary diseases, today presented clinical data for AP01, its novel formulation of inhaled pirfenidone, for the treatment of pulmonary fibrosis, supporting the Company’s planned Phase 2b trial in patients with progressive pulmonary fibrosis (PPF). Analysis from Avalyn’s ongoing ATLAS open-label extension study demonstrated that treatment with AP01 stabilized forced vital capacity (FVC) in patients with both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), with enhanced safety and tolerability compared to oral pirfenidone. Furthermore, findings from post-hoc analyses examining disease progression and Brainomix’s e-Lung biomarker scores support the Company’s selected dosing of 100 mg twice-daily and 50 mg twice-daily in the planned Phase 2b study.

Key Points: 
  • The data were presented in multiple poster presentations and featured events during the 2024 American Thoracic Society (ATS) International Conference held May 17-22, 2024, in San Diego, CA.
  • “Having dedicated decades to treating patients with respiratory diseases, I’ve seen firsthand the pressing need for new treatments.
  • Our excitement stems from the long-term data with AP01 that shows treatment of patients out to nearly four years, surpassing the average survival rates for patients with progressive disease.
  • These data support Avalyn’s selection of AP01 100 mg twice-daily and 50 mg twice-daily for the Company’s planned Phase 2b clinical trial.

voxeljet Showcases Its Next-Gen 3D Printers VJET X in Action at BMW Group: With 10x Faster Performance, the New 3D Printers Are Integrated Into a Fully Automated Additive Production Line

Retrieved on: 
星期三, 十月 25, 2023
Technology, Engineering, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, Machinery, Machine Tools, Metalworking & Metallurgy, Hardware, BMW Motorrad, 3D, MINI, B48, Patent, ICP, Head, Core, BMW Group Plant Dingolfing, Multimedia, Plant, Partnership, BMW, Sand, Fed, Rolls-Royce, 3D printing, Voxeljet

voxeljet AG (NASDAQ: VJET) and Loramendi demonstrate the world’s first fully automated additive serial 3D production line for sand cores, jointly developed as part of the Industrialization of Core Printing (ICP) cooperation project.

Key Points: 
  • voxeljet AG (NASDAQ: VJET) and Loramendi demonstrate the world’s first fully automated additive serial 3D production line for sand cores, jointly developed as part of the Industrialization of Core Printing (ICP) cooperation project.
  • A new video released today features the implementation of the first ICP production line at BMW Group's plant in Landshut, Germany.
  • The production of inorganic 3D printed cores has enabled BMW Group to advance the design of its engine components.
  • The inorganic 3D production line also significantly reduces the foundry’s emissions, as only water steam is produced during the casting process.